SRPT:NASDAQ
Sarepta Therapeutics Inc
$20.45
0.00%
(0.00) 1D
Sep 11, 4:00:00 PM GMT-4 · USD
search
All symbols
No data
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for SRPT...
Mkt. cap
2.16B
Avg. vol.
3.13M
Volume
2.37K
52-wk high
$25.32
52-wk low
$14.68
EPS
-$1.66
Beta
0.27
Shares outstanding
105.63M
No. of employees
835
Mkt. cap
2.16B
Avg. vol.
3.13M
Volume
2.37K
52-wk high
$25.32
52-wk low
$14.68
EPS
-$1.66
Beta
0.27
Shares outstanding
105.63M
No. of employees
835
Profile
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs. Wikipedia
About Sarepta Therapeutics Inc
Analyst ratings
Based on 17 analysts giving stock ratings to SRPT in the past 3 months
Hold
Buy
5
Hold
8
Sell
4
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for SRPT in the last 3 months.
Highest
Current $20.45
$38.00 (+85.82%)
Average
$22.88 (+11.88%)
Lowest
$5.00 (-75.55%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Yun Zhong Wedbush | Buy | Maintained | $35.00 | +71.1% | 09/08/2026 |
Mitchell Kapoor H.C. Wainwright | Sell | Reiterated | $5.00 | -75.6% | 09/09/2026 |
Anupam Rama J.P. Morgan | Hold | Maintained | $23.00 | +12.5% | 09/01/2026 |
Gavin Clark-Gartner Evercore ISI | Hold | Maintained | $19.00 | -7.1% | 08/10/2026 |
Eliana Merle Barclays | Hold | Maintained | $20.00 | -2.2% | 08/07/2026 |
Tazeen Ahmad Bank of America Securities | Sell | Reiterated | $18.00 | -12% | 08/06/2026 |
Kristen Kluska Cantor Fitzgerald | Hold | Maintained | $21.00 | +2.7% | 08/05/2026 |
Kostas Biliouris Oppenheimer | Buy | Maintained | $35.00 | +71.1% | 08/06/2026 |
Brian Abrahams RBC Capital | Hold | Maintained | $19.00 | -7.1% | 08/05/2026 |
Yanan Zhu Wells Fargo | Buy | Maintained | $38.00 | +85.8% | 08/06/2026 |
Michael Ulz Morgan Stanley | Hold | Reiterated | $25.00 | +22.2% | 08/06/2026 |
Biren Amin Piper Sandler | Hold | Maintained | $20.00 | -2.2% | 08/06/2026 |
Gil Blum Needham | Sell | Reiterated | - | - | 08/06/2026 |
Ritu Baral TD Cowen | Hold | Reiterated | $17.00 | -16.9% | 08/06/2026 |
Yigal Nochomovitz Citi | Sell | Maintained | $13.00 | -36.4% | 07/20/2026 |
Uy Ear Mizuho Securities | Buy | Maintained | $31.00 | +51.6% | 07/10/2026 |
Andy Chen Wolfe Research | Buy | Upgraded | $27.00 | +32% | 07/08/2026 |
Stephen Brozak WBB Securities | Buy | Maintained | $38.00 | +85.8% | 03/26/2026 |
Unknown Analyst WBB Securities | Buy | Maintained | $38.00 | +85.8% | 03/26/2026 |
David Hoang Deutsche Bank | Sell | Maintained | $14.00 | -31.5% | 03/26/2026 |
William Pickering Bernstein | Hold | Maintained | $20.00 | -2.2% | 03/25/2026 |
Joseph Schwartz Leerink Partners | Hold | Maintained | $15.00 | -26.7% | 03/25/2026 |
Unknown Analyst Guggenheim | Buy | Reiterated | $19.00 | -7.1% | 03/09/2026 |
Brian Skorney Robert W. Baird | Hold | Maintained | $20.00 | -2.2% | 02/26/2026 |
Salveen Richter Goldman Sachs | Hold | Maintained | $17.00 | -16.9% | 02/25/2026 |
Sami Corwin William Blair | Hold | Reiterated | - | - | 02/26/2026 |
Last report
Aug 5, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.64 / $0.48
+32.49%beat
arrow_upward
Revenue / Est. (USD)
401.25M / 369.62M
+8.56%beat
arrow_upward
Fiscal Q2 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 399.36M | 442.93M | 730.80M | 401.25M |
Cost of goods sold | 369.66M | 724.04M | 262.73M | 240.64M |
Cost of revenue | 369.66M | 724.04M | 262.73M | 240.64M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 91.89M | 128.30M | 108.95M | 107.60M |
Operating expense | 92.57M | 128.97M | 109.64M | 108.32M |
Total operating expenses | 462.24M | 853.02M | 372.37M | 348.96M |
Operating income | -62.88M | -410.08M | 358.43M | 52.29M |
Other non operating income | -702.00K | -338.00K | 1.16M | -246.00K |
EBT including unusual items | -194.05M | -278.30M | 343.17M | -1.75M |
EBT excluding unusual items | -63.90M | -423.20M | 344.24M | 36.74M |
Income tax expense | -14.10M | 4.55M | 12.22M | 3.14M |
Effective tax rate | 7.27% | -1.64% | 3.56% | -179.59% |
Other operating expenses | - | - | - | - |
Net income | -179.95M | -282.85M | 330.96M | -4.89M |
Net profit margin | -45.06% | -63.86% | 45.29% | -1.22% |
Earnings per share | -0.13 | -3.58 | 3.16 | 0.64 |
Interest and investment income | 7.25M | 8.07M | 6.36M | 6.21M |
Interest expense | -7.56M | -20.84M | -21.71M | -21.51M |
Net interest expenses | -316.00K | -12.77M | -15.35M | -15.30M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -44.43M | -404.83M | 369.03M | 62.70M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1